Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Xu Jiang, Sungyeun Bae, Deok Yong Yoon, Shin Jung Park, Jaeseong Oh, Joo-Youn Cho & Kyung-Sang Yu. (2023) Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects. Drug Design, Development and Therapy 17, pages 2137-2145.
Read now
Read now
Yao Chen, Xuejiao Qie, Wei Quan, Maomao Zeng, Fang Qin, Jie Chen, Benu Adhikari & Zhiyong He. (2023) Omnifarious fruit polyphenols: an omnipotent strategy to prevent and intervene diabetes and related complication?. Critical Reviews in Food Science and Nutrition 63:20, pages 4288-4324.
Read now
Read now
Bryce C Simes & Gordon G MacGregor. (2019) Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide. Diabetes, Metabolic Syndrome and Obesity 12, pages 2125-2136.
Read now
Read now
Marco Tuccori, Irma Convertino, Maria Teresa Galiulo, Alessandra Marino, Alice Capogrosso-Sansone & Corrado Blandizzi. (2017) Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. Expert Opinion on Drug Safety 16:10, pages 1133-1148.
Read now
Read now
Pantelis A. Sarafidis, Maria Eleni Alexandrou & Luis M. Ruilope. (2017) A review of chemical therapies for treating diabetic hypertension. Expert Opinion on Pharmacotherapy 18:9, pages 909-923.
Read now
Read now
Charles Shaefer, Debbie Hinnen & Christopher Sadler. (2016) Hypoglycemia and diabetes: increased need for awareness. Current Medical Research and Opinion 32:9, pages 1479-1486.
Read now
Read now
Rizwana Parveen, Nidhi Bharal Agarwal, Neelam Kaushal, Ghanshyam Mali & Sheikh Raisuddin. (2016) Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Expert Opinion on Pharmacotherapy 17:1, pages 105-115.
Read now
Read now
Charles F Shaefer$suffix/text()$suffix/text(), Pamela Kushner & Richard Aguilar. (2015) User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgraduate Medicine 127:8, pages 818-826.
Read now
Read now
James R. Gavin$suffix/text()$suffix/text(), Melanie J. Davies, Michael Davies, Ujjwala Vijapurkar, Maria Alba & Gary Meininger. (2015) The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Current Medical Research and Opinion 31:9, pages 1693-1702.
Read now
Read now
Devada Singh-Franco. (2015) Potential for dipeptidyl peptidase-4 inhibitor and sodium glucose cotransporter 2 inhibitor single-pill combinations. Expert Review of Endocrinology & Metabolism 10:3, pages 305-317.
Read now
Read now
Manfredi Rizzo, Noor Al-Busaidi & Ali A Rizvi. (2015) Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives. Expert Opinion on Pharmacotherapy 16:3, pages 281-284.
Read now
Read now
Marianna Maranghi, Anna Carnovale, Cosimo Durante, Giovanna Tarquini, Giusy Tiseo & Sebastiano Filetti. (2015) Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:1, pages 125-137.
Read now
Read now
Luke D Boyle & John PH Wilding. (2014) A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes. Expert Opinion on Drug Safety 13:11, pages 1535-1544.
Read now
Read now
Articles from other publishers (13)
Xueliang Wang, Zhe Wang, Di Liu, Hao Jiang, Chao Cai, Guoyun Li & Guangli Yu. (2022) Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease. Frontiers in Pharmacology 13.
Crossref
Crossref
Moein Ala, Mohammad Reza Fallahpour Khoshdel & Ahmad Reza Dehpour. (2022) Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats. Oxidative Medicine and Cellular Longevity 2022, pages 1-9.
Crossref
Crossref
Maria Elba Bandeira de Farias, Deborah Cristina de Lemos Araújo Queiroz & Fernanda Moura Victor. 2022. Endocrinology and Diabetes. Endocrinology and Diabetes
397
409
.
Yan-Rong Li, Chi-Hung Liu, Wei-Chiao Sun, Pei-Yi Fan, Feng-Hsuan Liu, Tien-Hsing Chen, Victor Chien-Chia Wu, Chihung Lin & Ching-Chung Hsiao. (2021) The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone. Journal of Personalized Medicine 11:9, pages 828.
Crossref
Crossref
Kenan Çadırcı, Özlem Özdemir Tozlu & Hasan Türkez. (2019) The in vitro cytotoxicity, genotoxicity and oxidative damage potential of dapagliflozin, on cultured human blood cells. Turkish Journal of Biochemistry 44:5, pages 692-698.
Crossref
Crossref
İrfan Karahan, Çağar Alp & Aşkın Güngüneş. (2018) Sodium-glucose co-transporter-2 inhibitors in Type 2 diabetes treatment. Ortadoğu Tıp Dergisi 10:3, pages 381-385.
Crossref
Crossref
Takuo Yoshimoto, Takayuki Furuki, Hiroyuki Kobori, Masaaki Miyakawa, Hitomi Imachi, Koji Murao & Akira Nishiyama. (2023) Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Urinary Excretion of Intact and Total Angiotensinogen in Patients with Type 2 Diabetes. Journal of Investigative Medicine 65:7, pages 1057-1061.
Crossref
Crossref
Éva Bokor, Sándor Kun, David Goyard, Marietta Tóth, Jean-Pierre Praly, Sébastien Vidal & László Somsák. (2017)
C
-Glycopyranosyl Arenes and Hetarenes: Synthetic Methods and Bioactivity Focused on Antidiabetic Potential
. Chemical Reviews 117:3, pages 1687-1764.
Crossref
Crossref
Shelly Pathania, Nishant Kashyap, Virender Singh, Ravi Shankar, Kapil Kumar & Ravindra K Rawal. (2016) Development and Recent Advancement of SGLT2 Inhibitors for the Treatment Regime of T2DM. Journal of Biomedicine 1:4.
Crossref
Crossref
Durgaprasad M. Kabade, Anand Koppad, Ameet Khatawkar, Savitri D Kabade & Afaq Ahmed. (2016) ORAL HYPOGLYCAEMIC AGENTS IN THE MANAGEMENT OF TYPE II DIABETES MELLITUS. Journal of Evidence Based Medicine and Healthcare 3:45, pages 2272-2282.
Crossref
Crossref
Mussa H. Almalki & Fahad Alshahrani. (2016) Options for Controlling Type 2 Diabetes during Ramadan. Frontiers in Endocrinology 7.
Crossref
Crossref
Jayant Kelwade, BipinKumar Sethi, SriV Nagesh & Ayesha Vaseem. (2014) A case of "pseudo-ketoacidosis". Indian Journal of Endocrinology and Metabolism 18:5, pages 743.
Crossref
Crossref
Hao-Wen Lin & Chin-Hsiao Tseng. (2014) A Review on the Relationship between SGLT2 Inhibitors and Cancer. International Journal of Endocrinology 2014, pages 1-6.
Crossref
Crossref